 | • レポートコード：GIR-107A12530 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、オピオイド誘発性便秘症のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。オピオイド誘発性便秘症の種類別市場規模（固体、液体）、用途別市場規模（ドラッグストア、病院、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・オピオイド誘発性便秘症の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AstraZeneca、Takeda Pharmaceutical、Bausch Health、Abbott、Bayer、Boehringer Ingelheim、C.B. Fleet、Cosmo Pharmaceuticals、Daewoong、Daiichi Sankyo、GlaxoSmithKline、Ironwood Pharmaceuticals、Johnson and Johnson、Merck、Mundipharma、Nektar Therapeutics、Pfizer、Progenics Pharmaceuticals、Shionogi、SLA Pharma、Sucampo、Synergy Pharmaceuticals、Theravance ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：固体、液体 ・用途別分析2016年-2026年：ドラッグストア、病院、その他 ・オピオイド誘発性便秘症の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・オピオイド誘発性便秘症のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・オピオイド誘発性便秘症のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・オピオイド誘発性便秘症の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・オピオイド誘発性便秘症の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Opioid-induced Constipation market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Opioid-induced Constipation size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Opioid-induced Constipation market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Opioid-induced Constipation market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Solid
Liquid
Market segment by Application, can be divided into
Drugstore
Hospital
Others
Market segment by players, this report covers
AstraZeneca
Takeda Pharmaceutical
Bausch Health
Abbott
Bayer
Boehringer Ingelheim
C.B. Fleet
Cosmo Pharmaceuticals
Daewoong
Daiichi Sankyo
GlaxoSmithKline
Ironwood Pharmaceuticals
Johnson and Johnson
Merck
Mundipharma
Nektar Therapeutics
Pfizer
Progenics Pharmaceuticals
Shionogi
SLA Pharma
Sucampo
Synergy Pharmaceuticals
Theravance
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Opioid-induced Constipation product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Opioid-induced Constipation, with revenue, gross margin and global market share of Opioid-induced Constipation from 2019 to 2021.
Chapter 3, the Opioid-induced Constipation competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Opioid-induced Constipation market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Opioid-induced Constipation research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Opioid-induced Constipation
1.2 Classification of Opioid-induced Constipation by Type
1.2.1 Overview: Global Opioid-induced Constipation Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Opioid-induced Constipation Revenue Market Share by Type in 2020
1.2.3 Solid
1.2.4 Liquid
1.3 Global Opioid-induced Constipation Market by Application
1.3.1 Overview: Global Opioid-induced Constipation Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Drugstore
1.3.3 Hospital
1.3.4 Others
1.4 Global Opioid-induced Constipation Market Size & Forecast
1.5 Global Opioid-induced Constipation Market Size and Forecast by Region
1.5.1 Global Opioid-induced Constipation Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Opioid-induced Constipation Market Size by Region, (2016-2021)
1.5.3 North America Opioid-induced Constipation Market Size and Prospect (2016-2026)
1.5.4 Europe Opioid-induced Constipation Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Opioid-induced Constipation Market Size and Prospect (2016-2026)
1.5.6 South America Opioid-induced Constipation Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Opioid-induced Constipation Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Opioid-induced Constipation Market Drivers
1.6.2 Opioid-induced Constipation Market Restraints
1.6.3 Opioid-induced Constipation Trends Analysis
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Opioid-induced Constipation Product and Solutions
2.1.4 AstraZeneca Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 Takeda Pharmaceutical
2.2.1 Takeda Pharmaceutical Details
2.2.2 Takeda Pharmaceutical Major Business
2.2.3 Takeda Pharmaceutical Opioid-induced Constipation Product and Solutions
2.2.4 Takeda Pharmaceutical Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Takeda Pharmaceutical Recent Developments and Future Plans
2.3 Bausch Health
2.3.1 Bausch Health Details
2.3.2 Bausch Health Major Business
2.3.3 Bausch Health Opioid-induced Constipation Product and Solutions
2.3.4 Bausch Health Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Bausch Health Recent Developments and Future Plans
2.4 Abbott
2.4.1 Abbott Details
2.4.2 Abbott Major Business
2.4.3 Abbott Opioid-induced Constipation Product and Solutions
2.4.4 Abbott Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Abbott Recent Developments and Future Plans
2.5 Bayer
2.5.1 Bayer Details
2.5.2 Bayer Major Business
2.5.3 Bayer Opioid-induced Constipation Product and Solutions
2.5.4 Bayer Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Bayer Recent Developments and Future Plans
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Opioid-induced Constipation Product and Solutions
2.6.4 Boehringer Ingelheim Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Boehringer Ingelheim Recent Developments and Future Plans
2.7 C.B. Fleet
2.7.1 C.B. Fleet Details
2.7.2 C.B. Fleet Major Business
2.7.3 C.B. Fleet Opioid-induced Constipation Product and Solutions
2.7.4 C.B. Fleet Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 C.B. Fleet Recent Developments and Future Plans
2.8 Cosmo Pharmaceuticals
2.8.1 Cosmo Pharmaceuticals Details
2.8.2 Cosmo Pharmaceuticals Major Business
2.8.3 Cosmo Pharmaceuticals Opioid-induced Constipation Product and Solutions
2.8.4 Cosmo Pharmaceuticals Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Cosmo Pharmaceuticals Recent Developments and Future Plans
2.9 Daewoong
2.9.1 Daewoong Details
2.9.2 Daewoong Major Business
2.9.3 Daewoong Opioid-induced Constipation Product and Solutions
2.9.4 Daewoong Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Daewoong Recent Developments and Future Plans
2.10 Daiichi Sankyo
2.10.1 Daiichi Sankyo Details
2.10.2 Daiichi Sankyo Major Business
2.10.3 Daiichi Sankyo Opioid-induced Constipation Product and Solutions
2.10.4 Daiichi Sankyo Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Daiichi Sankyo Recent Developments and Future Plans
2.11 GlaxoSmithKline
2.11.1 GlaxoSmithKline Details
2.11.2 GlaxoSmithKline Major Business
2.11.3 GlaxoSmithKline Opioid-induced Constipation Product and Solutions
2.11.4 GlaxoSmithKline Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 GlaxoSmithKline Recent Developments and Future Plans
2.12 Ironwood Pharmaceuticals
2.12.1 Ironwood Pharmaceuticals Details
2.12.2 Ironwood Pharmaceuticals Major Business
2.12.3 Ironwood Pharmaceuticals Opioid-induced Constipation Product and Solutions
2.12.4 Ironwood Pharmaceuticals Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Ironwood Pharmaceuticals Recent Developments and Future Plans
2.13 Johnson and Johnson
2.13.1 Johnson and Johnson Details
2.13.2 Johnson and Johnson Major Business
2.13.3 Johnson and Johnson Opioid-induced Constipation Product and Solutions
2.13.4 Johnson and Johnson Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Johnson and Johnson Recent Developments and Future Plans
2.14 Merck
2.14.1 Merck Details
2.14.2 Merck Major Business
2.14.3 Merck Opioid-induced Constipation Product and Solutions
2.14.4 Merck Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Merck Recent Developments and Future Plans
2.15 Mundipharma
2.15.1 Mundipharma Details
2.15.2 Mundipharma Major Business
2.15.3 Mundipharma Opioid-induced Constipation Product and Solutions
2.15.4 Mundipharma Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Mundipharma Recent Developments and Future Plans
2.16 Nektar Therapeutics
2.16.1 Nektar Therapeutics Details
2.16.2 Nektar Therapeutics Major Business
2.16.3 Nektar Therapeutics Opioid-induced Constipation Product and Solutions
2.16.4 Nektar Therapeutics Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Nektar Therapeutics Recent Developments and Future Plans
2.17 Pfizer
2.17.1 Pfizer Details
2.17.2 Pfizer Major Business
2.17.3 Pfizer Opioid-induced Constipation Product and Solutions
2.17.4 Pfizer Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Pfizer Recent Developments and Future Plans
2.18 Progenics Pharmaceuticals
2.18.1 Progenics Pharmaceuticals Details
2.18.2 Progenics Pharmaceuticals Major Business
2.18.3 Progenics Pharmaceuticals Opioid-induced Constipation Product and Solutions
2.18.4 Progenics Pharmaceuticals Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 Progenics Pharmaceuticals Recent Developments and Future Plans
2.19 Shionogi
2.19.1 Shionogi Details
2.19.2 Shionogi Major Business
2.19.3 Shionogi Opioid-induced Constipation Product and Solutions
2.19.4 Shionogi Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 Shionogi Recent Developments and Future Plans
2.20 SLA Pharma
2.20.1 SLA Pharma Details
2.20.2 SLA Pharma Major Business
2.20.3 SLA Pharma Opioid-induced Constipation Product and Solutions
2.20.4 SLA Pharma Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.20.5 SLA Pharma Recent Developments and Future Plans
2.21 Sucampo
2.21.1 Sucampo Details
2.21.2 Sucampo Major Business
2.21.3 Sucampo Opioid-induced Constipation Product and Solutions
2.21.4 Sucampo Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.21.5 Sucampo Recent Developments and Future Plans
2.22 Synergy Pharmaceuticals
2.22.1 Synergy Pharmaceuticals Details
2.22.2 Synergy Pharmaceuticals Major Business
2.22.3 Synergy Pharmaceuticals Opioid-induced Constipation Product and Solutions
2.22.4 Synergy Pharmaceuticals Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.22.5 Synergy Pharmaceuticals Recent Developments and Future Plans
2.23 Theravance
2.23.1 Theravance Details
2.23.2 Theravance Major Business
2.23.3 Theravance Opioid-induced Constipation Product and Solutions
2.23.4 Theravance Opioid-induced Constipation Revenue, Gross Margin and Market Share (2019-2021)
2.23.5 Theravance Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Opioid-induced Constipation Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Opioid-induced Constipation Players Market Share
3.2.2 Top 10 Opioid-induced Constipation Players Market Share
3.2.3 Market Competition Trend
3.3 Opioid-induced Constipation Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Opioid-induced Constipation Revenue and Market Share by Type (2016-2021)
4.2 Global Opioid-induced Constipation Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Opioid-induced Constipation Revenue Market Share by Application (2016-2021)
5.2 Opioid-induced Constipation Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Opioid-induced Constipation Revenue by Type (2016-2026)
6.2 North America Opioid-induced Constipation Revenue by Application (2016-2026)
6.3 North America Opioid-induced Constipation Market Size by Country
6.3.1 North America Opioid-induced Constipation Revenue by Country (2016-2026)
6.3.2 United States Opioid-induced Constipation Market Size and Forecast (2016-2026)
6.3.3 Canada Opioid-induced Constipation Market Size and Forecast (2016-2026)
6.3.4 Mexico Opioid-induced Constipation Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Opioid-induced Constipation Revenue by Type (2016-2026)
7.2 Europe Opioid-induced Constipation Revenue by Application (2016-2026)
7.3 Europe Opioid-induced Constipation Market Size by Country
7.3.1 Europe Opioid-induced Constipation Revenue by Country (2016-2026)
7.3.2 Germany Opioid-induced Constipation Market Size and Forecast (2016-2026)
7.3.3 France Opioid-induced Constipation Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Opioid-induced Constipation Market Size and Forecast (2016-2026)
7.3.5 Russia Opioid-induced Constipation Market Size and Forecast (2016-2026)
7.3.6 Italy Opioid-induced Constipation Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Opioid-induced Constipation Revenue by Type (2016-2026)
8.2 Asia-Pacific Opioid-induced Constipation Revenue by Application (2016-2026)
8.3 Asia-Pacific Opioid-induced Constipation Market Size by Region
8.3.1 Asia-Pacific Opioid-induced Constipation Revenue by Region (2016-2026)
8.3.2 China Opioid-induced Constipation Market Size and Forecast (2016-2026)
8.3.3 Japan Opioid-induced Constipation Market Size and Forecast (2016-2026)
8.3.4 South Korea Opioid-induced Constipation Market Size and Forecast (2016-2026)
8.3.5 India Opioid-induced Constipation Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Opioid-induced Constipation Market Size and Forecast (2016-2026)
8.3.7 Australia Opioid-induced Constipation Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Opioid-induced Constipation Revenue by Type (2016-2026)
9.2 South America Opioid-induced Constipation Revenue by Application (2016-2026)
9.3 South America Opioid-induced Constipation Market Size by Country
9.3.1 South America Opioid-induced Constipation Revenue by Country (2016-2026)
9.3.2 Brazil Opioid-induced Constipation Market Size and Forecast (2016-2026)
9.3.3 Argentina Opioid-induced Constipation Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Opioid-induced Constipation Revenue by Type (2016-2026)
10.2 Middle East & Africa Opioid-induced Constipation Revenue by Application (2016-2026)
10.3 Middle East & Africa Opioid-induced Constipation Market Size by Country
10.3.1 Middle East & Africa Opioid-induced Constipation Revenue by Country (2016-2026)
10.3.2 Turkey Opioid-induced Constipation Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Opioid-induced Constipation Market Size and Forecast (2016-2026)
10.3.4 UAE Opioid-induced Constipation Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Opioid-induced Constipation Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Opioid-induced Constipation Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Opioid-induced Constipation Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Opioid-induced Constipation Revenue (USD Million) by Region (2016-2021)
Table 5. Global Opioid-induced Constipation Revenue Market Share by Region (2021-2026)
Table 6. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 7. AstraZeneca Major Business
Table 8. AstraZeneca Opioid-induced Constipation Product and Solutions
Table 9. AstraZeneca Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Takeda Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 11. Takeda Pharmaceutical Major Business
Table 12. Takeda Pharmaceutical Opioid-induced Constipation Product and Solutions
Table 13. Takeda Pharmaceutical Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Bausch Health Corporate Information, Head Office, and Major Competitors
Table 15. Bausch Health Major Business
Table 16. Bausch Health Opioid-induced Constipation Product and Solutions
Table 17. Bausch Health Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Abbott Corporate Information, Head Office, and Major Competitors
Table 19. Abbott Major Business
Table 20. Abbott Opioid-induced Constipation Product and Solutions
Table 21. Abbott Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Bayer Corporate Information, Head Office, and Major Competitors
Table 23. Bayer Major Business
Table 24. Bayer Opioid-induced Constipation Product and Solutions
Table 25. Bayer Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 27. Boehringer Ingelheim Major Business
Table 28. Boehringer Ingelheim Opioid-induced Constipation Product and Solutions
Table 29. Boehringer Ingelheim Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. C.B. Fleet Corporate Information, Head Office, and Major Competitors
Table 31. C.B. Fleet Major Business
Table 32. C.B. Fleet Opioid-induced Constipation Product and Solutions
Table 33. C.B. Fleet Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Cosmo Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 35. Cosmo Pharmaceuticals Major Business
Table 36. Cosmo Pharmaceuticals Opioid-induced Constipation Product and Solutions
Table 37. Cosmo Pharmaceuticals Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Daewoong Corporate Information, Head Office, and Major Competitors
Table 39. Daewoong Major Business
Table 40. Daewoong Opioid-induced Constipation Product and Solutions
Table 41. Daewoong Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Daiichi Sankyo Corporate Information, Head Office, and Major Competitors
Table 43. Daiichi Sankyo Major Business
Table 44. Daiichi Sankyo Opioid-induced Constipation Product and Solutions
Table 45. Daiichi Sankyo Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 47. GlaxoSmithKline Major Business
Table 48. GlaxoSmithKline Opioid-induced Constipation Product and Solutions
Table 49. GlaxoSmithKline Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Ironwood Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 51. Ironwood Pharmaceuticals Major Business
Table 52. Ironwood Pharmaceuticals Opioid-induced Constipation Product and Solutions
Table 53. Ironwood Pharmaceuticals Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Johnson and Johnson Corporate Information, Head Office, and Major Competitors
Table 55. Johnson and Johnson Major Business
Table 56. Johnson and Johnson Opioid-induced Constipation Product and Solutions
Table 57. Johnson and Johnson Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Merck Corporate Information, Head Office, and Major Competitors
Table 59. Merck Major Business
Table 60. Merck Opioid-induced Constipation Product and Solutions
Table 61. Merck Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Mundipharma Corporate Information, Head Office, and Major Competitors
Table 63. Mundipharma Major Business
Table 64. Mundipharma Opioid-induced Constipation Product and Solutions
Table 65. Mundipharma Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Nektar Therapeutics Corporate Information, Head Office, and Major Competitors
Table 67. Nektar Therapeutics Major Business
Table 68. Nektar Therapeutics Opioid-induced Constipation Product and Solutions
Table 69. Nektar Therapeutics Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Pfizer Corporate Information, Head Office, and Major Competitors
Table 71. Pfizer Major Business
Table 72. Pfizer Opioid-induced Constipation Product and Solutions
Table 73. Pfizer Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Progenics Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 75. Progenics Pharmaceuticals Major Business
Table 76. Progenics Pharmaceuticals Opioid-induced Constipation Product and Solutions
Table 77. Progenics Pharmaceuticals Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. Shionogi Corporate Information, Head Office, and Major Competitors
Table 79. Shionogi Major Business
Table 80. Shionogi Opioid-induced Constipation Product and Solutions
Table 81. Shionogi Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. SLA Pharma Corporate Information, Head Office, and Major Competitors
Table 83. SLA Pharma Major Business
Table 84. SLA Pharma Opioid-induced Constipation Product and Solutions
Table 85. SLA Pharma Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 86. Sucampo Corporate Information, Head Office, and Major Competitors
Table 87. Sucampo Major Business
Table 88. Sucampo Opioid-induced Constipation Product and Solutions
Table 89. Sucampo Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 90. Synergy Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 91. Synergy Pharmaceuticals Major Business
Table 92. Synergy Pharmaceuticals Opioid-induced Constipation Product and Solutions
Table 93. Synergy Pharmaceuticals Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 94. Theravance Corporate Information, Head Office, and Major Competitors
Table 95. Theravance Major Business
Table 96. Theravance Opioid-induced Constipation Product and Solutions
Table 97. Theravance Opioid-induced Constipation Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 98. Global Opioid-induced Constipation Revenue (USD Million) by Players (2019-2021)
Table 99. Global Opioid-induced Constipation Revenue Share by Players (2019-2021)
Table 100. Breakdown of Opioid-induced Constipation by Company Type (Tier 1, Tier 2 and Tier 3)
Table 101. Opioid-induced Constipation Players Head Office, Products and Services Provided
Table 102. Opioid-induced Constipation Mergers & Acquisitions in the Past Five Years
Table 103. Opioid-induced Constipation New Entrants and Expansion Plans
Table 104. Global Opioid-induced Constipation Revenue (USD Million) by Type (2016-2021)
Table 105. Global Opioid-induced Constipation Revenue Share by Type (2016-2021)
Table 106. Global Opioid-induced Constipation Revenue Forecast by Type (2021-2026)
Table 107. Global Opioid-induced Constipation Revenue by Application (2016-2021)
Table 108. Global Opioid-induced Constipation Revenue Forecast by Application (2021-2026)
Table 109. North America Opioid-induced Constipation Revenue by Type (2016-2021) & (USD Million)
Table 110. North America Opioid-induced Constipation Revenue by Type (2021-2026) & (USD Million)
Table 111. North America Opioid-induced Constipation Revenue by Application (2016-2021) & (USD Million)
Table 112. North America Opioid-induced Constipation Revenue by Application (2021-2026) & (USD Million)
Table 113. North America Opioid-induced Constipation Revenue by Country (2016-2021) & (USD Million)
Table 114. North America Opioid-induced Constipation Revenue by Country (2021-2026) & (USD Million)
Table 115. Europe Opioid-induced Constipation Revenue by Type (2016-2021) & (USD Million)
Table 116. Europe Opioid-induced Constipation Revenue by Type (2021-2026) & (USD Million)
Table 117. Europe Opioid-induced Constipation Revenue by Application (2016-2021) & (USD Million)
Table 118. Europe Opioid-induced Constipation Revenue by Application (2021-2026) & (USD Million)
Table 119. Europe Opioid-induced Constipation Revenue by Country (2016-2021) & (USD Million)
Table 120. Europe Opioid-induced Constipation Revenue by Country (2021-2026) & (USD Million)
Table 121. Asia-Pacific Opioid-induced Constipation Revenue by Type (2016-2021) & (USD Million)
Table 122. Asia-Pacific Opioid-induced Constipation Revenue by Type (2021-2026) & (USD Million)
Table 123. Asia-Pacific Opioid-induced Constipation Revenue by Application (2016-2021) & (USD Million)
Table 124. Asia-Pacific Opioid-induced Constipation Revenue by Application (2021-2026) & (USD Million)
Table 125. Asia-Pacific Opioid-induced Constipation Revenue by Region (2016-2021) & (USD Million)
Table 126. Asia-Pacific Opioid-induced Constipation Revenue by Region (2021-2026) & (USD Million)
Table 127. South America Opioid-induced Constipation Revenue by Type (2016-2021) & (USD Million)
Table 128. South America Opioid-induced Constipation Revenue by Type (2021-2026) & (USD Million)
Table 129. South America Opioid-induced Constipation Revenue by Application (2016-2021) & (USD Million)
Table 130. South America Opioid-induced Constipation Revenue by Application (2021-2026) & (USD Million)
Table 131. South America Opioid-induced Constipation Revenue by Country (2016-2021) & (USD Million)
Table 132. South America Opioid-induced Constipation Revenue by Country (2021-2026) & (USD Million)
Table 133. Middle East & Africa Opioid-induced Constipation Revenue by Type (2016-2021) & (USD Million)
Table 134. Middle East & Africa Opioid-induced Constipation Revenue by Type (2021-2026) & (USD Million)
Table 135. Middle East & Africa Opioid-induced Constipation Revenue by Application (2016-2021) & (USD Million)
Table 136. Middle East & Africa Opioid-induced Constipation Revenue by Application (2021-2026) & (USD Million)
Table 137. Middle East & Africa Opioid-induced Constipation Revenue by Country (2016-2021) & (USD Million)
Table 138. Middle East & Africa Opioid-induced Constipation Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Opioid-induced Constipation Picture
Figure 2. Global Opioid-induced Constipation Revenue Market Share by Type in 2020
Figure 3. Solid
Figure 4. Liquid
Figure 5. Opioid-induced Constipation Revenue Market Share by Application in 2020
Figure 6. Drugstore Picture
Figure 7. Hospital Picture
Figure 8. Others Picture
Figure 9. Global Opioid-induced Constipation Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Opioid-induced Constipation Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Opioid-induced Constipation Revenue Market Share by Region (2016-2026)
Figure 12. Global Opioid-induced Constipation Revenue Market Share by Region in 2020
Figure 13. North America Opioid-induced Constipation Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Opioid-induced Constipation Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Opioid-induced Constipation Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Opioid-induced Constipation Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Middle East and Africa Opioid-induced Constipation Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Opioid-induced Constipation Market Drivers
Figure 19. Opioid-induced Constipation Market Restraints
Figure 20. Opioid-induced Constipation Market Trends
Figure 21. AstraZeneca Recent Developments and Future Plans
Figure 22. Takeda Pharmaceutical Recent Developments and Future Plans
Figure 23. Bausch Health Recent Developments and Future Plans
Figure 24. Abbott Recent Developments and Future Plans
Figure 25. Bayer Recent Developments and Future Plans
Figure 26. Boehringer Ingelheim Recent Developments and Future Plans
Figure 27. C.B. Fleet Recent Developments and Future Plans
Figure 28. Cosmo Pharmaceuticals Recent Developments and Future Plans
Figure 29. Daewoong Recent Developments and Future Plans
Figure 30. Daiichi Sankyo Recent Developments and Future Plans
Figure 31. GlaxoSmithKline Recent Developments and Future Plans
Figure 32. Ironwood Pharmaceuticals Recent Developments and Future Plans
Figure 33. Johnson and Johnson Recent Developments and Future Plans
Figure 34. Merck Recent Developments and Future Plans
Figure 35. Mundipharma Recent Developments and Future Plans
Figure 36. Nektar Therapeutics Recent Developments and Future Plans
Figure 37. Pfizer Recent Developments and Future Plans
Figure 38. Progenics Pharmaceuticals Recent Developments and Future Plans
Figure 39. Shionogi Recent Developments and Future Plans
Figure 40. SLA Pharma Recent Developments and Future Plans
Figure 41. Sucampo Recent Developments and Future Plans
Figure 42. Synergy Pharmaceuticals Recent Developments and Future Plans
Figure 43. Theravance Recent Developments and Future Plans
Figure 44. Global Opioid-induced Constipation Revenue Share by Players in 2020
Figure 45. Opioid-induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 46. Global Top 3 Players Opioid-induced Constipation Revenue Market Share in 2020
Figure 47. Global Top 10 Players Opioid-induced Constipation Revenue Market Share in 2020
Figure 48. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 49. Global Opioid-induced Constipation Revenue Share by Type in 2020
Figure 50. Global Opioid-induced Constipation Market Share Forecast by Type (2021-2026)
Figure 51. Global Opioid-induced Constipation Revenue Share by Application in 2020
Figure 52. Global Opioid-induced Constipation Market Share Forecast by Application (2021-2026)
Figure 53. North America Opioid-induced Constipation Sales Market Share by Type (2016-2026)
Figure 54. North America Opioid-induced Constipation Sales Market Share by Application (2016-2026)
Figure 55. North America Opioid-induced Constipation Revenue Market Share by Country (2016-2026)
Figure 56. United States Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Canada Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Mexico Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Europe Opioid-induced Constipation Sales Market Share by Type (2016-2026)
Figure 60. Europe Opioid-induced Constipation Sales Market Share by Application (2016-2026)
Figure 61. Europe Opioid-induced Constipation Revenue Market Share by Country (2016-2026)
Figure 62. Germany Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. France Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. United Kingdom Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Russia Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Italy Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Asia-Pacific Opioid-induced Constipation Sales Market Share by Type (2016-2026)
Figure 68. Asia-Pacific Opioid-induced Constipation Sales Market Share by Application (2016-2026)
Figure 69. Asia-Pacific Opioid-induced Constipation Revenue Market Share by Region (2016-2026)
Figure 70. China Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Japan Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. South Korea Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. India Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Southeast Asia Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Australia Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. South America Opioid-induced Constipation Sales Market Share by Type (2016-2026)
Figure 77. South America Opioid-induced Constipation Sales Market Share by Application (2016-2026)
Figure 78. South America Opioid-induced Constipation Revenue Market Share by Country (2016-2026)
Figure 79. Brazil Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Argentina Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Middle East and Africa Opioid-induced Constipation Sales Market Share by Type (2016-2026)
Figure 82. Middle East and Africa Opioid-induced Constipation Sales Market Share by Application (2016-2026)
Figure 83. Middle East and Africa Opioid-induced Constipation Revenue Market Share by Country (2016-2026)
Figure 84. Turkey Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 85. Saudi Arabia Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 86. UAE Opioid-induced Constipation Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 87. Methodology
Figure 88. Research Process and Data Source
世界の化学療法誘発性骨髄抑制治療市場 2021：企業別、地域別、種類・用途別 The Chemotherapy-Induced Myelosuppression Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain opt…- 世界の化学療法誘発性脱毛用頭皮クール機器市場 2021：企業別、地域別、種類・用途別 The Scalp Cool Devices for Chemotherapy Induced Hair Loss market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value cha…
- 世界の化学療法誘発性末梢神経障害治療市場 2021：企業別、地域別、種類・用途別 The Chemotherapy Induced Peripheral Neuropathy Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chai…
- 世界の化学療法誘発性貧血治療薬市場 2021：企業別、地域別、種類・用途別 The Chemotherapy Induced Anemia Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trad…
- 世界のレーザー誘起破壊分光法（LIBS）アナライザー市場 2021：企業別、地域別、種類・用途別 The Laser Induced Breakdown Spectroscopy (LIBS) Analyzers market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value cha…